

Francisco Antunes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1404666/publications.pdf>

Version: 2024-02-01

93
papers

4,902
citations

87888

38
h-index

95266

68
g-index

93
all docs

93
docs citations

93
times ranked

4572
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study. <i>Healthcare (Switzerland)</i> , 2021, 9, 797.	2.0	4
2	Handling of Fresh Vegetables: Knowledge, Hygienic Behavior of Vendors, Public Health in Maputo Markets, Mozambique. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6302.	2.6	15
3	Towards a Global Perspective of Environmental Health: Defining the Research Grounds of an Institute of Environmental Health. <i>Sustainability</i> , 2020, 12, 8963.	3.2	1
4	Atazanavir sulfate + cobicistat for the treatment of HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 569-576.	4.4	9
5	<i>Pneumocystis jirovecii</i> and Pneumocystosis. , 2017, , 215-254.		5
6	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 338-340.	2.1	21
7	<i>Cryptosporidium</i> spp., <i>Giardia duodenalis</i> , <i>Enterocytozoon bieneusi</i> and Other Intestinal Parasites in Young Children in Lobata Province, Democratic Republic of São Tomé and Príncipe. <i>PLoS ONE</i> , 2014, 9, e97708.	2.5	48
8	<i>Toxoplasma gondii</i> prevalence in cats from Lisbon and in pigs from centre and south of Portugal. <i>Veterinary Parasitology</i> , 2014, 200, 8-12.	1.8	31
9	Long-term risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis. <i>BMC Nephrology</i> , 2013, 14, 32.	1.8	16
10	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results. <i>Journal of Infectious Diseases</i> , 2013, 208, 32-39.	4.0	104
11	Study of the epidemiology of <i>Pneumocystis carinii</i> f. sp. <i>suis</i> in abattoir swine in Portugal. <i>Medical Mycology</i> , 2013, 51, 66-71.	0.7	9
12	Direct treatment costs of HIV/AIDS in Portugal. <i>Revista De Saude Publica</i> , 2013, 47, 865-872.	1.7	9
13	Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for <i>Pneumocystis</i> Pneumonia: A Pilot Study in Mice. <i>PLoS ONE</i> , 2013, 8, e70619.	2.5	49
14	Tuberculosis with malaria or HIV co-infection in a large hospital in Luanda, Angola. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 269-272.	1.2	16
15	Baseline susceptibility of primary HIV-2 to entry inhibitors. <i>Antiviral Therapy</i> , 2012, 17, 565-570.	1.0	44
16	Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. <i>Aids</i> , 2012, 26, 2275-2284.	2.2	23
17	<i>Pneumocystis jirovecii</i> multilocus genotyping in pooled DNA samples: a new approach for clinical and epidemiological studies. <i>Clinical Microbiology and Infection</i> , 2012, 18, E177-E184.	6.0	20
18	Genetic Diversity and Drug Resistance Profiles in HIV Type 1- and HIV Type 2-Infected Patients from Cape Verde Islands. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 510-522.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Microsporidia as emerging pathogens and the implication for public health: A 10-year study on HIV-positive and -negative patients. <i>International Journal for Parasitology</i> , 2012, 42, 197-205.	3.1	89
20	The case of the disappearing mycobacteria in Ziehl-Neelsen-stained smears. <i>International Journal of Infectious Diseases</i> , 2011, 15, e291.	3.3	1
21	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.	2.2	79
22	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. <i>Antiviral Therapy</i> , 2011, 16, 339-348.	1.0	89
23	Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, S1-S2.	3.8	1
24	Cell-Associated Viral Burden Provides Evidence of Ongoing Viral Replication in Aviremic HIV-2-Infected Patients. <i>Journal of Virology</i> , 2011, 85, 2429-2438.	3.4	50
25	Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3888-3894.	0.7	33
26	Clinical Relevance of Multiple Single-Nucleotide Polymorphisms in <i>Pneumocystis jirovecii</i> Pneumonia: Development of a Multiplex PCR-Single-Base-Extension Methodology. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1810-1815.	3.9	35
27	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome—defining malignancies. <i>Cancer</i> , 2010, 116, 5306-5315.	4.1	120
28	Population structure of <i>Pneumocystis jirovecii</i> isolated from immunodeficiency virus-positive patients. <i>Infection, Genetics and Evolution</i> , 2010, 10, 192-199.	2.3	49
29	Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. <i>BMC Nephrology</i> , 2010, 11, 9.	1.8	65
30	Identification of relevant single-nucleotide polymorphisms in <i>Pneumocystis jirovecii</i> : relationship with clinical data. <i>Clinical Microbiology and Infection</i> , 2010, 16, 878-884.	6.0	41
31	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	3.0	51
32	20 Years of HIV-2 Infection in Portugal: Trends and Changes in Epidemiology. <i>Clinical Infectious Diseases</i> , 2009, 48, 1166-1167.	5.8	50
33	Genetic characterization of the UCS and Kex1 loci of <i>Pneumocystis jirovecii</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 175-178.	2.9	16
34	Occurrence of <i>Cryptosporidium</i> and <i>Giardia</i> genotypes and subtypes in raw and treated water in Portugal. <i>Letters in Applied Microbiology</i> , 2009, 48, 732-7.	2.2	43
35	Acute kidney injury in patients with sepsis: a contemporary analysis. <i>International Journal of Infectious Diseases</i> , 2009, 13, 176-181.	3.3	91
36	<i>Pneumocystis jirovecii</i> multilocus genotyping profiles in patients from Portugal and Spain. <i>Clinical Microbiology and Infection</i> , 2008, 14, 356-362.	6.0	61

#	ARTICLE	IF	CITATIONS
37	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. <i>Retrovirology</i> , 2008, 5, 78.	2.0	23
38	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 694-698.	3.0	53
39	Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. <i>Aids</i> , 2008, 22, 2257-2265.	2.2	16
40	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732.	2.2	85
41	Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results. <i>Clinical Infectious Diseases</i> , 2007, 44, 1484-1492.	5.8	143
42	Acute renal failure in critically ill HIV-infected patients. <i>Critical Care</i> , 2007, 11, 404.	5.8	12
43	Prognostic utility of RIFLE for acute renal failure in patients with sepsis. <i>Critical Care</i> , 2007, 11, 408.	5.8	42
44	Acute renal failure in patients with sepsis. <i>Critical Care</i> , 2007, 11, 411.	5.8	59
45	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/?L who were assigned to 7.5 MIU interleukin-2. <i>HIV Medicine</i> , 2007, 8, 112-123.	2.2	7
46	Low CD4 T-cell counts despite low levels of circulating HIV: Insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease. <i>Clinical Immunology</i> , 2007, 125, 67-75.	3.2	9
47	An assessment of the RIFLE criteria for acute renal failure in critically ill HIV-infected patients. <i>Critical Care</i> , 2006, 11, 401.	5.8	31
48	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.	2.2	39
49	Distribution of <i>Cryptosporidium</i> Species and Subtypes in Water Samples in Portugal: A Preliminary Study. <i>Journal of Eukaryotic Microbiology</i> , 2006, 53, S24-S25.	1.7	16
50	Genotypes of <i>Enterocytozoon bienersi</i> in Mammals in Portugal. <i>Journal of Eukaryotic Microbiology</i> , 2006, 53, S61-S64.	1.7	74
51	Multilocus Genotyping of <i>Pneumocystis jirovecii</i> in Immunocompromised Patients: Preliminary Results. <i>Journal of Eukaryotic Microbiology</i> , 2006, 53, S104-S105.	1.7	6
52	Distribution of <i>Cryptosporidium</i> subtypes in humans and domestic and wild ruminants in Portugal. <i>Parasitology Research</i> , 2006, 99, 287-292.	1.6	165
53	Genetic characterization of the dihydrofolate reductase gene of <i>Pneumocystis jirovecii</i> isolates from Portugal. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1246-1249.	3.0	22
54	Identification of Potentially Human-Pathogenic <i>Enterocytozoon bienersi</i> Genotypes in Various Birds. <i>Applied and Environmental Microbiology</i> , 2006, 72, 7380-7382.	3.1	62

#	ARTICLE	IF	CITATIONS
55	Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial. <i>Clinical Infectious Diseases</i> , 2006, 43, 1347-1356.	5.8	85
56	Identification and determination of the viability of <i>Giardia lamblia</i> cysts and <i>Cryptosporidium parvum</i> and <i>Cryptosporidium hominis</i> oocysts in human fecal and water supply samples by fluorescent in situ hybridization (FISH) and monoclonal antibodies. <i>Parasitology Research</i> , 2005, 98, 48-53.	1.6	36
57	Occurrence and molecular characterization of <i>Cryptosporidium</i> spp. in mammals and reptiles at the Lisbon Zoo. <i>Parasitology Research</i> , 2005, 97, 108-112.	1.6	38
58	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	2.2	472
59	Detection of <i>Pneumocystis jirovecii</i> dihydropteroate synthase polymorphisms in patients with <i>Pneumocystis pneumonia</i> . <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 766-771.	1.5	24
60	Tuberculosis, a re-emergent disease. <i>European Journal of Radiology</i> , 2005, 55, 154-157.	2.6	37
61	Is there a gender shift in HCV infection?. <i>International Journal of Infectious Diseases</i> , 2005, 9, 230-231.	3.3	2
62	<i>Cryptosporidium felis</i> and <i>C. meleagridis</i> in Persons with HIV, Portugal. <i>Emerging Infectious Diseases</i> , 2004, 10, 2256-2257.	4.3	47
63	HIV-2: the Portuguese Connection. <i>Clinical Infectious Diseases</i> , 2004, 39, 1553-1554.	5.8	6
64	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
65	The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. <i>Cancer</i> , 2004, 100, 2644-2654.	4.1	132
66	HIV Infection and Non-tuberculous Mycobacteria: How Important in Southern European Countries?. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 685-686.	1.5	2
67	Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting. <i>European Journal of Epidemiology</i> , 2003, 19, 577-584.	5.7	22
68	Microsatellite Analysis of <i>Cryptosporidium hominis</i> and <i>C. parvum</i> in Portugal: a Preliminary Study. <i>Journal of Eukaryotic Microbiology</i> , 2003, 50, 529-530.	1.7	21
69	Microsporidia Detection in Stools from Pets and Animals from the Zoo in Portugal: A Preliminary Study. <i>Journal of Eukaryotic Microbiology</i> , 2003, 50, 581-582.	1.7	20
70	Dihydropteroate Synthase (DHPS) Genotyping by PCR-RFLP Analysis of <i>Pneumocystis jirovecii</i> Repeated Isolates from HIV-Infected Patients: A Preliminary Study. <i>Journal of Eukaryotic Microbiology</i> , 2003, 50, 607-608.	1.7	3
71	<i>Pneumocystis jirovecii</i> Carriage in Portuguese Immunocompetent Patients: Preliminary Results. <i>Journal of Eukaryotic Microbiology</i> , 2003, 50, 647-648.	1.7	6
72	<i>Pneumocystis jirovecii</i> in Portuguese immunocompromised patients: association of specific ITS genotypes with treatment failure, bad clinical outcome and childhood. <i>Infection, Genetics and Evolution</i> , 2003, 3, 281-285.	2.3	25

#	ARTICLE	IF	CITATIONS
73	CRYPTOSPORIDIUM SPP. IN RUMINANTS AT THE LISBON ZOO. <i>Journal of Zoo and Wildlife Medicine</i> , 2003, 34, 352-356.	0.6	13
74	Mutations in the dihydropteroate synthase gene of <i>Pneumocystis jiroveci</i> isolates from Portuguese patients with <i>Pneumocystis pneumonia</i> . <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 516-520.	2.5	24
75	Subgenotype Analysis of <i>Cryptosporidium</i> Isolates from Humans, Cattle, and Zoo Ruminants in Portugal. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2744-2747.	3.9	461
76	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. <i>Aids</i> , 2003, 17, 987-999.	2.2	151
77	Diagnostic Use of 3 Techniques for Identification of Microsporidian Spores Among AIDS Patients in Portugal. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 591-593.	1.5	10
78	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	2.2	61
79	Multilocus Genotyping of <i>Cryptosporidium</i> Isolates from Human HIV-Infected and Animal Hosts. <i>Journal of Eukaryotic Microbiology</i> , 2001, 48, 17s-18s.	1.7	31
80	Methodology of the Diagnosis of Microsporidiosis in Urine and Pulmonary Specimens from AIDS Patients. <i>Journal of Eukaryotic Microbiology</i> , 2001, 48, 69s-70s.	1.7	5
81	PCR-RFLP Analysis of the DHPS gene for the Study of Resistance of <i>Pneumocystis carinii</i> to Sulpha Drugs in Patients with Co-infection PCP/HIV. <i>Journal of Eukaryotic Microbiology</i> , 2001, 48, 148s-149s.	1.7	10
82	A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience. <i>Antiviral Therapy</i> , 2001, 6, 89-96.	1.0	5
83	Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. , 2000, 61, 111-116.		89
84	PCR-RFLP analysis of <i>Cryptosporidium parvum</i> isolates from HIV-infected patients in Lisbon, Portugal. <i>Annals of Tropical Medicine and Parasitology</i> , 2000, 94, 291-297.	1.6	12
85	Bulk Cytokine Production versus Frequency of Cytokine-Producing Cells in HIV1 Infection before and during HAART. <i>Clinical Immunology</i> , 2000, 97, 162-170.	3.2	9
86	Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1370-1374.	3.9	81
87	Recombinant CagA enzyme-linked immunosorbent assay and western immunoblot for the detection of serum antibodies to <i>Helicobacter pylori</i> . <i>Clinical Microbiology and Infection</i> , 2000, 6, 149.	6.0	0
88	A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. <i>Aids</i> , 1999, 13, 2411-2420.	2.2	26
89	Quantitation of Human Immunodeficiency Virus Type 2 DNA in Peripheral Blood Mononuclear Cells by Using a Quantitative-Competitive PCR Assay. <i>Journal of Clinical Microbiology</i> , 1999, 37, 453-456.	3.9	28
90	Changes in use of antiretroviral therapy in regions of Europe over time. <i>Aids</i> , 1998, 12, 2031-2039.	2.2	51

#	ARTICLE	IF	CITATIONS
91	A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 333, 408-413.	27.0	326
92	Human immunodeficiency virus infection and systolic myocardial performance. International Journal of Angiology, 1994, 3, 148-153.	0.6	0
93	Seroprevalence of SARS-CoV-2 among Health Care Personnel in Portugal. , 0, , .		0